Astrogenetix is issuing the following statement applauding NASA's commitment to extend the life of the International Space Station (ISS) to 2020 or beyond.
(Vocus) February 1, 2010 -- Astrogenetix is issuing the following statement applauding NASA's commitment to extend the life of the International Space Station (ISS) to 2020 or beyond.
Thomas B. Pickens III, Chairman of Astrogenetix, Inc.:
“We are excited to see such a significant commitment from the Obama Administration and NASA to extend the International Space Station to 2020 or beyond. The ISS National Lab provides us with one of our country’s most unique environments for conducting scientific research. Astrogentix is very proud of our results in discovering the salmonella vaccine during the National Lab Pathfinder missions. The vision outlined today will allow for continued discoveries of important vaccines like MRSA and provide a platform for many more discoveries in the future.”
About Astrogenetix, Incorporated
A subsidiary of Astrotech Corporation (Nasdaq: ASTC), Astrogenetix is a biotechnology company formed to commercialize biotechnology products processed in the unique environment of microgravity. The Company offers a turn-key platform for pre-flight sample preparation, flight hardware, mission planning and operations, crew training and certification processes needed within the highly regulated and complex environment of manned space flight.
The statements in this document may contain forward-looking statements that are made pursuant to the Safe Harbor provisions of the Private Securities Litigation Reform Act of 1995. Such forward-looking statements are subject to risks, trends, and uncertainties that could cause actual results to be materially different from the forward-looking statement. These factors include, but are not limited to, continued government support and f
Copyright©2010 Vocus, Inc.
All rights reserved